The Study of Pharmacological Efficacy in Dry Mulberry Burirum-60 in MildStage of Alzheimer's Disease

Abstract

Alzheimer’s Disease is a condition in which occurs in the area concerning the deteriation of brain function. This condition of disease is not completely curative treatment by medicines and always happens in the eldery with ages over 55 years old. However it can delay and maintain the condition of the stages of deteriation of brain function. In this experiment. We used Morus alba Linn. Burirum 60 leaves collected from Mahasarakham University Research Plantation Field, the Division of Research Innovation and were prepared as a powder in capsule form to control the incidence and maintain brain function condition in Mild stage of Alzheimer’s disease patients. Morus alba Linn. contains many minerals and vitamin A, vitamin B, vitamin B3, vitamin B12, vitamin C, essential amino acids, Zinc, Magnesium, Sodium, deoxynojirimycin, GABA, Phytosterol , Calcium, Potassium, folic acid etc.. The samples of this research were collected from silk weaving women, ages of 55-70 years old in Silk Innovation Weaving Village, supported by Mahasarakham University. The samples were divided into 4 groups as follows: group no.1 of feeding silkworms weaving women and intake Morus alba Burirum 60 capsule, group no.2 of feeding silkworms weaving women  and intake placebo, group no.3 of non feeding silkworm weaving women and intake Morus alba Burirum 60 capsule, group no.4 of non feeding silkworms weaving women and intake the placebo. All samples were tested with Cognitive Testing Scale and the selected samples were Mild cognitive memory function group. The dosage of Morus alba capsule would have 2 capsules after meals , once daily for 3 months and all the samples were tested for cognitive memory function using the scales of Sage1, Mini-Mental state Examination (MMSE), Functional Assessment Stage tool (Fast) for evaluation and confirmation of the efficacy of Mulberry (Morus alba Burirum 60) effecting the brain function. The data were tested with Wilcoxon Signed Rank Test and Kruskal Wallis statistical analysis. The result revealed that each 4 groups of Group no.1, no.2, no.3, and no.4 were 3.00, 1.50, 3.00 and 2.00 respectively. It showed that in each group had indicated mean scores with statistical significant difference at p-value 0.05. It showed the development of changing scores tested by SAGE1 scale within the group. Then we compared the mean scores difference among or in between groups by using the Kruskal Wallis statistical method. The result found that the mean rank score among 4 groups before the experiment were 14.10, 12.70, 7.30 and 7.90 respectively and the mean rank score among 4 groups after the experiment were 17.70, 8.70, 11.00 and 4.60 respectively. The higher rank of each groups indicated the higher development in obtaining the scores of SAGE1 tested by Kruskal Wallis after the experiment by oral intake of Morus alba Linn. Burirum-60 capsules with the dosage of 200 mg daily for 3 months. It showed the development of cognitive memory function by increasing the ranking scores of group no.1, group no.3 and group no.2 respectively. The suggestion of this study for the future research is to increase the size of samples and clinical confirmed with CT-SCAN or NMR in order to measure the comparison of improvement in the density and brain image before and after the experiment and also the duration of administering or intake Morus alba Linn. Burirum-60 should be recommended to extend longer period of time and may be increase in the daily dosage.  
Key words: Mild cognitive memory impairment; MMSE; SAGE1; FAST; Alzheimer Disease